[Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
OBJECTIVE
To evaluate the diagnostic usefulness of serum osteoprotegerin (OPG) in prostate cancer bone metastasis.


METHODS
Serum osteoprotegerin were measured by ELISA assay in 30 healthy men, 30 patients with benign prostatic hyperplasia, 66 patients with prostate cancer including 36 without bone metastasis (30 with localized cancer, 6 with lymph node metastasis) and 30 with bone metastasis. The results associated with clinical data were calculated statistically.


RESULTS
Serum osteoprotegerin were significantly increased in patients with bone metastasis compared with others (P<0.001). OPG level had a positive correlation with either prostate specific antigen (PSA) or Alkaline phosphatase (ALP) level (r=0.427, 0.277; P<0.001); and a positive correlation with either Gleason score or grade (r=0.427, 0.277; P<0.001). ROC analysis proved that OPG had better diagnostic accuracy than ALP for detecting bone metastasis in prostate cancer.


CONCLUSIONS
Serum osteoprotegerin could be used as a marker for diagnosis of bone metastasis in prostate cancer.
Chen
Hai-xin
HX
Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
Li
Han-zhong
HZ
Li
Hong-jun
HJ
Shi
Bing-bing
BB
Jin
Wei
W
Cheng
Xin-qi
XQ
D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood / Q000175:diagnosis / Q000556:secondary*; D006801:Humans; D008297:Male; D053244:Osteoprotegerin / Q000097:blood*; D011471:Prostatic Neoplasms / Q000473:pathology*; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D053244:Osteoprotegerin